SCHEMBL30983500

SCHEMBL30983500

C[C@@H](CCOc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2cccc(Cl)c2)c(Cl)c1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.33
▸ PIK3CD O00329 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ IDH1 O75874 1/20 0.33
▸ S1PR1 P21453 2/20 0.33
▸ MAOB P27338 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ S1PR5 Q9H228 1/20 0.33
▸ SRC P12931 2/20 0.32
▸ S1PR3 Q99500 1/20 0.32
▸ HTR6 P50406 2/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR7 P34969 1/20 0.32
▸ LTB4R Q15722 1/20 0.32
▸ AVPR1B P47901 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983374 1.00 CNR1 (0.35) CNR1TLR7PIK3CDKMT2AIDH1
SCHEMBL30983474 1.00 CNR1 (0.35) CNR1TLR7PIK3CDKMT2AIDH1
SCHEMBL31268960 0.97 LTB4R (0.34) CNR1TLR7PIK3CDKMT2AS1PR1
SCHEMBL31269183 0.94 PIK3CD (0.34) PIK3CDKMT2AS1PR1S1PR5S1PR3
SCHEMBL31269306 0.93 PIK3CD (0.32) PIK3CDKMT2AS1PR1S1PR3PPARG
SCHEMBL31269301 0.93 S1PR1 (0.35) CNR1TLR7PIK3CDKMT2AS1PR1
SCHEMBL31269322 0.93 PPARG (0.37) TLR7PIK3CDKMT2AHTR6MEN1
SCHEMBL30983982 0.93 CNR1 (0.34) CNR1PIK3CDKMT2AIDH1MAOB
SCHEMBL31268767 0.93 PPARG (0.37) TLR7PIK3CDKMT2AHTR6MEN1
SCHEMBL31269103 0.93 ALOX5AP (0.33) PIK3CDKMT2AS1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB CNR1 4278/4885TLR7 4408/4885PIK3CD 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback